FIELD: pharmacology.
SUBSTANCE: invention relates to medicine and can be used for the application of the hydrochloride salt of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazole-1-yl)-3-(trifluoromethyl)phenyl]benzamide in the form of monohydrate (nilotinib) for the manufacture of a drug for the treatment of chronic myeloid leukemia. Thus, the hydrochloride salt of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazole-1-yl)-3-(trifluoromethyl)phenyl]benzamide in the form of monohydrate and pharmaceutically acceptable carriers are dispersed in apple sauce.
EFFECT: flexibility of dosing, reduction of difficulty in swallowing, bioequivalence of therapeutic results in the treatment of patients with chronic myeloid leukemia.
1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS CONTAINING NILOTINIB OR ITS SALTS | 2007 |
|
RU2469707C2 |
| OPENING CYCLES OF LACTONES AND LACTAMS | 2010 |
|
RU2550691C2 |
| STAUROSPORIN DERIVATIVES USED FOR TREATING ALVEOLAR RHABDOMYOBLASTOMA | 2006 |
|
RU2443421C2 |
| COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | 2007 |
|
RU2481840C2 |
| PHTHALAZINES ELICITING ANGIOGENESIS INHIBITORY ACTIVITY | 1998 |
|
RU2207132C2 |
| APPLICATION OF PYRIMIDYLAMINOBENZAMIDES FOR TREATMENT OF DISEASES SENSITIVE TO MODULATION OF KINASE Tie-2 ACTIVITY | 2006 |
|
RU2404776C2 |
| ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
| METHOD FOR SYNTHESIS OF 5-(METHYL-1H-IMIDAZOL-1-YL)-3-(TRIFLUOROMETHYL) BENZAMIDE | 2006 |
|
RU2444520C2 |
| COMBINATION OF PYRIMIDYLAMINOBENZAMIDE AND mTOR KINASE INHIBITOR | 2006 |
|
RU2443418C2 |
| ORAL PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475237C2 |
